<h4>Introduction</h4>Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); however, severe immune effector cell-associated adverse events, including cytokine release syndrome (CRS) and neurotoxicity, remain major clinical challenges. Here, CD19 is linked to diffuse large B-cell lymphoma.